HeyJaredClin Obes
- Indexed articles, last 90 days
- 4
- Latest publication
- Sep 9, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Aug 17, 2026
Latest articles
Tirzepatide Beats Semaglutide for Weight Loss, Not Safety (opens the original)
Read excerpt
Among adults with overweight or obesity, tirzepatide was associated with greater weight reduction and glycemic improvement than semaglutide but was also linked to a higher risk for serious adverse events, according to a meta-analysis of head-to-head studies. "Among adults with overweight or obesity, tirzepatide is associated with greater weight reduction and modestly greater glycaemic improvement compared with semaglutide, although these benefits may be accompanied by a higher risk of serious ad
Early Dietitian Visits Linked to Successful Weight Loss (opens the original)
Read excerpt
Among patients with overweight or obesity receiving dietetic treatment in Dutch primary care, one-third of patients achieved clinically meaningful weight loss of ≥ 5% within 1 year, and most of them did so within the first 3 months of treatment. "These results underline that the early phase of treatment is important for initiating weight change, and that the number of visits plays a central role in achieving and sustaining clinically meaningful outcomes. Dietitians may consider more intense supp
Obesity Class III Linked to Death Risk in Younger Adults (opens the original)
Read excerpt
Obesity class III was associated with significantly increased risk for all-cause and cause-specific mortality in adults younger than 65 years, while minimal differences in mortality risk were observed across obesity classes in adults 65 years and older. "These differences should be considered when designing obesity management strategies, as they highlight the need for more aggressive approaches for these populations," the authors of the study wrote. The study was led by Amir Yazdanparast, School
Semaglutide and Depression: No Clear Link Found (opens the original)
Read excerpt
The use of semaglutide was not associated with an increased risk for depression compared with placebo or other antidiabetic/antiobesity agents, but the evidence was limited and of very low certainty. "Because the evidence base is limited, heterogeneous and partly derived from spontaneous-reporting systems, these findings should be interpreted cautiously. Clinicians should continue routine baseline assessment and follow-up monitoring for psychiatric symptoms, particularly in patients with pre-e
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.